Printer Friendly

CARDIORHYTHM UNVEILS NEW GENERATION OF EP PRODUCTS TO DIAGNOSE AND TREAT TACHYCARDIAS

 CARDIORHYTHM UNVEILS NEW GENERATION OF EP PRODUCTS
 TO DIAGNOSE AND TREAT TACHYCARDIAS
 DALLAS, April 13 /PRNewswire/ -- CardioRhythm(TM) today unveiled the first of a new generation of advanced electrophysiology products for the diagnosis and treatment of fast-rate arrhythmias, or tachycardias, at the spring meeting of the American College of Cardiology held at the Dallas Convention Center.
 CardioRhythm is introducing its Torqr(TM) series of diagnostic electrode catheters and the Voyagr(TM) series of fully steerable catheters for advanced mapping procedures of the heart's electrical pacing system. It is also previewing its RF Ablatr(TM) series of fully steerable therapeutic catheters and its Atakr(TM) RF Generation for use in Radio Frequency Catheter Ablation (RFCA), a new percutaneous procedure for investigational treatment of tachycardias and pending clearance by the Food and Drug Administration. Upon FDA approval, CardioRhythm will be conducting a multi-center clinical study of its RFCA products.
 Co-founder Harry S. Robbins, president and chief executive officer of CardioRhythm (formerly Arrhythmia Technologies Inc.), said the company was founded to commercialize proprietary technology aimed at improving the quality of life for the millions of patients who suffer from tachycardias. "Angioplasty, or PTCA (percutaneous translumenal coronary angioplasty), was a major medical advance of the 1980s," explained Robbins. "Like PTCA, radio frequency cardiac ablation is poised to become the minimally invasive success story of the 1990s. But unlike PTCA, RFCA offers tachycardia patients the possibility of curing their condition."
 Torqr and Voyagr Diagnostic Catheters
 Meeting the demand for reduced procedure time and x-ray exposure for both patient and physician, CardioRhythm's catheters offer unprecedented maneuverability and precise placement. For advanced mapping procedures, the Voyagr is the only fully maneuverable catheter to offer 360 degrees steerability, true one-to-one torque and a unique lateral deflection mechanism, allowing access to difficult-to-reach areas of the heart and stable electrode contact with the target issue. With its ergonomic shapeable handle, the user can vary the tip's curve up to 270 degrees in any plane.
 For standard diagnostic EP applications, the Torqr electrode catheter combines advanced extrusion, wire-braid processing and patented design technologies that provide one-to-one torque control. Its composite construction virtually eliminates "whipping" common to other electrode catheters, making it easy to manipulate within the chambers of the heart.
 RF Ablatr Therapeutic Catheter,
 Atakr Ablation System
 The RF Ablatr therapeutic catheter offers all of the ergonomic features of the Voyagr series, plus a unique sensing system that allows real-time monitoring of the catheter tip temperature during RF energy application. For use in conjunction with the RF Ablatr, the Atakr RF Generator is a lightweight, compact pole-mountable system designed to produce the highest quality optimized RF signal for cardiac ablation. Ablation electrode temperature is controlled via analog and digital computer electronics for enhanced lesion-size control and improved patient safety.
 Focused exclusively on serving the professional needs of electrophysiologists, San Jose, Calif.-based CardioRhythm was established to develop, manufacture and market a complete line of medical products to diagnose and treat rhythm abnormalities involving the heart's electrical pacing system.
 -0- 4/13/92
 /CONTACT: Harry S. Robbins, president and CEO of CardioRhythm, 408-943-6510; or Versaggi & Associates, 408-358-4162, for CardioRhythm/ CO: CardioRhythm ST: California, Texas IN: MTC SU: PDT


GK-TS -- NY001 -- 7564 04/13/92 08:37 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:535
Previous Article:USAIR LOWERS FLORIDA FARES FROM NORTHEAST DESTINATIONS
Next Article:PINKERTON ANNOUNCES COO TO RESUME FORMER ROLE


Related Articles
MEDTRONIC AGREES TO ACQUIRE CARDIORHYTHM, ENTERS ABLATION MARKET
MEDTRONIC COMPLETES ACQUISITION OF CARDIORHYTHM, EXPANDING ITS TACHYARRHYTHMIA BUSINESS
FDA ADVISORY PANEL TO CONSIDER MEDTRONIC RF CARDIAC ABLATION SYSTEM AT MEETING DECEMBER 5
Irvine Biomedical Receives CE Mark for Super-4 Catheter Ablation Systems for Atrial Fibrillation
Boston Scientific Receives FDA Clearance For.
EP MedSystems Announces Release Date and Conference Call Time for Fourth Quarter 2005 Financial Results.
Reminder - EP MedSystems Announces Release Date and Conference Call Time for Fourth Quarter 2005 Financial Results.
EP MedSystems Announces Release Date and Conference Call Time for First Quarter 2006 Financial Results.
Reminder - EP MedSystems Announces Release Date and Conference Call Time for First Quarter 2006 Financial Results.
EP MedSystems Announces Release Date and Conference Call Time for Second Quarter 2006 Financial Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters